REGENERON PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
REGENERON PHARMACEUTICALS, INC. (REGN) reported Payments to Acquire Marketable Securities of $4.71 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $1.95B, a 31.70% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $2.76B, a 8.53% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $2.04B, a 4.65% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $3.52B, a 23.33% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2025 was $10.96B, a 34.06% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2024 was $16.62B, a 42.69% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2023 was $11.65B, a 55.53% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2022 was $7.49B, a 6.24% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.95B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $4.71B 10-Q · filed 2026-07-30 | $6.75B derived: sum of 3 quarters · filed 2026-07-30 | $10.27B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $2.76B 10-Q · filed 2026-04-29 | $4.80B derived: sum of 2 quarters · filed 2026-04-29 | $8.32B derived: sum of 3 quarters · filed 2026-04-29 | $11.17B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $2.04B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $5.56B derived: sum of 2 quarters · filed 2026-02-04 | $8.42B derived: sum of 3 quarters · filed 2026-07-30 | $10.96B 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $3.52B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $6.38B derived: sum of 2 quarters · filed 2026-07-30 | $8.91B 10-Q · filed 2025-10-28 | $10.87B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $2.86B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $5.39B 10-Q · filed 2026-07-30 | $7.35B derived: sum of 3 quarters · filed 2026-07-30 | $11.94B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $2.54B 10-Q · filed 2026-04-29 | $4.49B derived: sum of 2 quarters · filed 2026-04-29 | $9.08B derived: sum of 3 quarters · filed 2026-04-29 | $13.50B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $1.95B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $6.54B derived: sum of 2 quarters · filed 2026-02-04 | $10.96B derived: sum of 3 quarters · filed 2026-02-04 | $16.62B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $4.59B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $9.01B derived: sum of 2 quarters · filed 2025-10-28 | $14.66B 10-Q · filed 2025-10-28 | $16.80B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $4.42B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $10.07B 10-Q · filed 2025-08-01 | $12.21B derived: sum of 3 quarters · filed 2026-02-04 | $15.45B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $5.66B 10-Q · filed 2025-04-29 | $7.79B derived: sum of 2 quarters · filed 2026-02-04 | $11.03B derived: sum of 3 quarters · filed 2026-02-04 | $15.55B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $2.13B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $5.37B derived: sum of 2 quarters · filed 2026-02-04 | $9.90B derived: sum of 3 quarters · filed 2026-02-04 | $11.65B 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $3.24B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $7.76B derived: sum of 2 quarters · filed 2024-10-31 | $9.51B 10-Q · filed 2024-10-31 | $12.66B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $4.52B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $6.27B 10-Q · filed 2024-08-01 | $9.41B derived: sum of 3 quarters · filed 2025-02-05 | $9.98B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $1.75B 10-Q · filed 2024-05-02 | $4.89B derived: sum of 2 quarters · filed 2025-02-05 | $5.46B derived: sum of 3 quarters · filed 2025-02-05 | $6.93B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $3.14B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $3.71B derived: sum of 2 quarters · filed 2025-02-05 | $5.18B derived: sum of 3 quarters · filed 2025-02-05 | $7.49B 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $570.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.04B derived: sum of 2 quarters · filed 2023-11-02 | $4.34B 10-Q · filed 2023-11-02 | $6.52B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $1.47B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.77B 10-Q · filed 2023-08-03 | $5.95B derived: sum of 3 quarters · filed 2024-02-05 | $8.94B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $2.31B 10-Q · filed 2023-05-04 | $4.49B derived: sum of 2 quarters · filed 2024-02-05 | $7.47B derived: sum of 3 quarters · filed 2024-02-05 | $8.00B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $2.18B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $5.16B derived: sum of 2 quarters · filed 2024-02-05 | $5.69B derived: sum of 3 quarters · filed 2024-02-05 | $7.05B 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $2.99B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.51B derived: sum of 2 quarters · filed 2022-11-03 | $4.87B 10-Q · filed 2022-11-03 | $5.47B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $526.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $1.89B 10-Q · filed 2022-08-03 | $2.48B derived: sum of 3 quarters · filed 2023-02-06 | $3.59B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | $1.36B 10-Q · filed 2022-05-04 | $1.96B derived: sum of 2 quarters · filed 2023-02-06 | $3.07B derived: sum of 3 quarters · filed 2023-02-06 | $3.89B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $598.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $1.71B derived: sum of 2 quarters · filed 2023-02-06 | $2.53B derived: sum of 3 quarters · filed 2023-02-06 | $3.24B 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $1.11B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.93B derived: sum of 2 quarters · filed 2021-11-04 | $2.64B 10-Q · filed 2021-11-04 | $3.01B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $819.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.53B 10-Q · filed 2021-08-05 | $1.90B derived: sum of 3 quarters · filed 2022-02-07 | $2.55B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $714.30M 10-Q · filed 2021-05-06 | $1.08B derived: sum of 2 quarters · filed 2022-02-07 | $1.73B derived: sum of 3 quarters · filed 2022-02-07 | $2.88B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $367.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $1.01B derived: sum of 2 quarters · filed 2022-02-07 | $2.16B derived: sum of 3 quarters · filed 2022-02-07 | $3.20B 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $645.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.79B derived: sum of 2 quarters · filed 2020-11-05 | $2.83B 10-Q · filed 2020-11-05 | $3.15B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $1.15B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $2.19B 10-Q · filed 2020-08-05 | $2.50B derived: sum of 3 quarters · filed 2021-02-08 | $2.85B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $1.04B 10-Q · filed 2020-05-05 | $1.35B derived: sum of 2 quarters · filed 2021-02-08 | $1.70B derived: sum of 3 quarters · filed 2021-02-08 | $2.28B derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $311.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $664.30M derived: sum of 2 quarters · filed 2021-02-08 | $1.24B derived: sum of 3 quarters · filed 2021-02-08 | $1.85B 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $352.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $932.30M derived: sum of 2 quarters · filed 2019-11-05 | $1.53B 10-Q · filed 2019-11-05 | $1.53B 10-Q · filed 2018-11-06 | $1.93B derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $579.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.18B 10-Q · filed 2019-08-06 | $1.18B 10-Q · filed 2018-08-02 | $1.57B derived: sum of 3 quarters · filed 2020-02-07 | $1.98B derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $601.30M 10-Q · filed 2019-05-07 | $601.31M 10-Q · filed 2018-05-03 | $994.75M derived: sum of 2 quarters · filed 2020-02-07 | $1.40B derived: sum of 3 quarters · filed 2020-02-07 | $1.67B derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $393.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $799.79M derived: sum of 2 quarters · filed 2020-02-07 | $1.07B derived: sum of 3 quarters · filed 2020-02-07 | $1.28B 10-K · filed 2020-02-07 | $1.28B 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $406.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $675.05M derived: sum of 2 quarters · filed 2018-11-06 | $883.75M 10-Q · filed 2018-11-06 | $1.09B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $268.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $477.41M 10-Q · filed 2018-08-02 | $680.65M derived: sum of 3 quarters · filed 2019-02-07 | $1.06B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $208.69M 10-Q · filed 2018-05-03 | $411.94M derived: sum of 2 quarters · filed 2019-02-07 | $789.15M derived: sum of 3 quarters · filed 2019-02-07 | $1.02B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $203.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $580.46M derived: sum of 2 quarters · filed 2019-02-07 | $809.40M derived: sum of 3 quarters · filed 2019-02-07 | $809.40M 10-K · filed 2019-02-07 | $809.42M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $377.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $606.15M derived: sum of 2 quarters · filed 2017-11-08 | $606.15M 10-Q · filed 2017-11-08 | $613.12M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $228.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $228.94M 10-Q · filed 2017-08-03 | $235.91M derived: sum of 3 quarters · filed 2018-02-08 | $445.20M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 | $6.96M derived: sum of 2 quarters · filed 2018-02-08 | $216.26M derived: sum of 3 quarters · filed 2018-02-08 | $461.33M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $216.26M derived: sum of 2 quarters · filed 2018-02-08 | $461.33M derived: sum of 3 quarters · filed 2018-02-08 | $557.11M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $209.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $454.37M derived: sum of 2 quarters · filed 2016-11-04 | $550.14M 10-Q · filed 2016-11-04 | $635.89M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $245.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $340.84M 10-Q · filed 2016-08-04 | $426.60M derived: sum of 3 quarters · filed 2017-02-09 | $530.52M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $95.78M 10-Q · filed 2016-05-05 | $181.53M derived: sum of 2 quarters · filed 2017-02-09 | $285.45M derived: sum of 3 quarters · filed 2017-02-09 | $406.08M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2014-12-31 | $85.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $189.68M derived: sum of 2 quarters · filed 2017-02-09 | $310.31M derived: sum of 3 quarters · filed 2017-02-09 | $564.19M 10-K · filed 2017-02-09 | ||||
| 2014-09-30 | $103.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $224.56M derived: sum of 2 quarters · filed 2015-11-04 | $478.44M 10-Q · filed 2015-11-04 | $578.40M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | $120.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $374.51M 10-Q · filed 2015-08-04 | $474.48M derived: sum of 3 quarters · filed 2016-02-11 | $669.14M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | $253.88M 10-Q · filed 2015-05-07 | $353.84M derived: sum of 2 quarters · filed 2016-02-11 | $548.51M derived: sum of 3 quarters · filed 2016-02-11 | $649.92M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $99.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $294.63M derived: sum of 2 quarters · filed 2016-02-11 | $396.04M derived: sum of 3 quarters · filed 2016-02-11 | $577.28M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | $194.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $296.08M derived: sum of 2 quarters · filed 2014-11-04 | $477.31M 10-Q · filed 2014-11-04 | $550.00M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $101.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $282.64M 10-Q · filed 2014-08-05 | $355.33M derived: sum of 3 quarters · filed 2015-02-12 | $482.68M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $181.24M 10-Q · filed 2014-05-08 | $180.92M 10-Q · filed 2013-05-03 | $253.93M derived: sum of 2 quarters · filed 2015-02-12 | $381.27M derived: sum of 3 quarters · filed 2015-02-12 | $603.61M derived: sum of 4 quarters · filed 2015-02-12 | |||
| 2012-12-31 | $72.69M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $200.04M derived: sum of 2 quarters · filed 2015-02-12 | $422.38M derived: sum of 3 quarters · filed 2015-02-12 | $470.94M 10-K · filed 2015-02-12 | $470.39M 10-K · filed 2013-02-15 | |||
| 2012-09-30 | $127.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $349.68M derived: sum of 2 quarters · filed 2013-11-05 | $398.25M 10-Q · filed 2013-11-05 | $523.11M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | $222.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $270.91M 10-Q · filed 2013-08-06 | $395.76M derived: sum of 3 quarters · filed 2014-02-13 | $495.66M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | $48.57M 10-Q · filed 2013-05-03 | $173.42M derived: sum of 2 quarters · filed 2014-02-13 | $273.32M derived: sum of 3 quarters · filed 2014-02-13 | $273.32M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | $124.85M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $224.75M derived: sum of 2 quarters · filed 2014-02-13 | $224.75M derived: sum of 3 quarters · filed 2014-02-13 | $240.39M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | $99.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $99.90M derived: sum of 2 quarters · filed 2012-10-24 | $115.54M 10-Q · filed 2012-10-24 | $479.00M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $15.64M 10-Q · filed 2012-07-25 | $379.10M derived: sum of 3 quarters · filed 2013-02-15 | $398.59M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $15.64M 10-Q · filed 2012-04-26 | $379.10M derived: sum of 2 quarters · filed 2013-02-15 | $398.59M derived: sum of 3 quarters · filed 2013-02-15 | $443.17M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $363.46M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $382.96M derived: sum of 2 quarters · filed 2013-02-15 | $427.53M derived: sum of 3 quarters · filed 2013-02-15 | $605.12M 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $19.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $64.07M derived: sum of 2 quarters · filed 2011-10-27 | $241.66M 10-Q · filed 2011-10-27 | $251.00M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $44.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $222.17M 10-Q · filed 2011-07-28 | $231.50M derived: sum of 3 quarters · filed 2012-02-21 | $316.85M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $177.59M 10-Q · filed 2011-05-03 | $186.93M derived: sum of 2 quarters · filed 2012-02-21 | $272.28M derived: sum of 3 quarters · filed 2012-02-21 | |||||
| 2009-12-31 | $9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $94.68M derived: sum of 2 quarters · filed 2012-02-21 | $200.00M 10-K · filed 2012-02-21 | |||||
| 2009-09-30 | $85.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $190.67M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $105.31M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $581.14M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |